DE3036390A1 - Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid - Google Patents
Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acidInfo
- Publication number
- DE3036390A1 DE3036390A1 DE19803036390 DE3036390A DE3036390A1 DE 3036390 A1 DE3036390 A1 DE 3036390A1 DE 19803036390 DE19803036390 DE 19803036390 DE 3036390 A DE3036390 A DE 3036390A DE 3036390 A1 DE3036390 A1 DE 3036390A1
- Authority
- DE
- Germany
- Prior art keywords
- general formula
- alkyl
- compounds
- pyrrolo
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000006243 chemical reaction Methods 0.000 title claims description 7
- 230000020335 dealkylation Effects 0.000 title claims description 6
- 238000006900 dealkylation reaction Methods 0.000 title claims description 6
- 230000003110 anti-inflammatory effect Effects 0.000 title description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 title 2
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 title 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 title 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 19
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 14
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 13
- 150000002367 halogens Chemical class 0.000 claims abstract description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 5
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 5
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 4
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims abstract description 3
- 125000001769 aryl amino group Chemical group 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 150000004944 pyrrolopyrimidines Chemical class 0.000 claims description 12
- -1 amino, hydroxy Chemical group 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 229920000137 polyphosphoric acid Polymers 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 150000003233 pyrroles Chemical class 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 150000004675 formic acid derivatives Chemical class 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- PHXQIAWFIIMOKG-UHFFFAOYSA-N NClO Chemical compound NClO PHXQIAWFIIMOKG-UHFFFAOYSA-N 0.000 claims description 2
- 150000005840 aryl radicals Chemical class 0.000 claims description 2
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 235000011007 phosphoric acid Nutrition 0.000 claims description 2
- 150000003016 phosphoric acids Chemical class 0.000 claims description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 2
- 239000013543 active substance Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 238000001816 cooling Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- ROWKJAVDOGWPAT-UHFFFAOYSA-N Acetoin Chemical compound CC(O)C(C)=O ROWKJAVDOGWPAT-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006264 debenzylation reaction Methods 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- ODZTXUXIYGJLMC-UHFFFAOYSA-N 2-hydroxycyclohexan-1-one Chemical compound OC1CCCCC1=O ODZTXUXIYGJLMC-UHFFFAOYSA-N 0.000 description 1
- NVVPXBSOUBMECG-UHFFFAOYSA-N 4-chloro-5,6-dimethyl-7h-pyrrolo[2,3-d]pyrimidine Chemical compound C1=NC(Cl)=C2C(C)=C(C)NC2=N1 NVVPXBSOUBMECG-UHFFFAOYSA-N 0.000 description 1
- WDLIZNULNYTMOG-UHFFFAOYSA-N 5,6-dimethyl-1,7-dihydropyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=NC(O)=C2C(C)=C(C)NC2=N1 WDLIZNULNYTMOG-UHFFFAOYSA-N 0.000 description 1
- PXHWVPTTWWSNJU-UHFFFAOYSA-N 5,6-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=NC(N)=C2C(C)=C(C)NC2=N1 PXHWVPTTWWSNJU-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000028419 Styrax benzoin Species 0.000 description 1
- 235000000126 Styrax benzoin Nutrition 0.000 description 1
- 235000008411 Sumatra benzointree Nutrition 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960002130 benzoin Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- DDRPCXLAQZKBJP-UHFFFAOYSA-N furfurylamine Chemical compound NCC1=CC=CO1 DDRPCXLAQZKBJP-UHFFFAOYSA-N 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- GFAZHVHNLUBROE-UHFFFAOYSA-N hydroxymethyl propionaldehyde Natural products CCC(=O)CO GFAZHVHNLUBROE-UHFFFAOYSA-N 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Neue Pyrrolo-Pyrimidine, . Verfahren zu ihrer HerstellungNew pyrrolo-pyrimidines,. Process for their manufacture
und ihre Verwendung bei der Herstellung von biologischen Wirkstoffen Die vorliegende Erfindung betrifft ein neues chemisch eigenartiges Verfahren zur Herstellung von neuen Pyrrolo-Pyrimidinen die als Zwischenprodukte für die Synthese von biologischen Wirkstoffen, insbesondere von Antiphlogistika verwendet werden können.and their use in the manufacture of biological agents The present invention relates to a new chemically unique process for Production of new pyrrolo-pyrimidines which are used as intermediates for the synthesis can be used by biological agents, in particular by anti-inflammatory drugs can.
Es ist bereits bekannt geworden, sekundäre oder tertiäre Amine zu debenzylieren oder zu dealkylieren. Diese Reaktionen beruhen normalerweise auf der Hydrogenolyse mit Palladiumkatalysatoren oder auf der Reduktion mit Natrium in flüssigem Ammoniak (F.W. Korte, Methodicum Chimicum, 6, S. 598 (1974)). Wenn das Amin Bestandteil eines heterocyclischen Systems isst,so führen diese üblichen Verfahren in den bisher'bekannten Fällen nicht zum Erfolg (T. Denzel, Arch. Pharm. (Weinheim) 307, 177 (1974) und J. Chem. Soc. Perkin 1, 1979, 938-942).It has already become known to use secondary or tertiary amines debenzylate or dealkylate. These reactions are usually based on the Hydrogenolysis with palladium catalysts or on the reduction with sodium in liquid Ammonia (F.W. Korte, Methodicum Chimicum, 6, p. 598 (1974)). When the amine component of a heterocyclic system, these usual processes lead to those previously known Cases not successful (T. Denzel, Arch. Pharm. (Weinheim) 307, 177 (1974) and J. Chem. Soc. Perkin 1, 1979, 938-942).
Es ist weiterhin bekannt, Verbindungen mit heterocyclischem Aminteil mit Selendioxid oder mit Polyphosphorsäure zu defurfurylieren (T. Denzel ot al, Arch. Pharm. (Weinheim) 309, 486 (1976)), Pyrrolo-* Pyrimidine, die in Position 7 benzyliert oder furfuryliert sind, lassen sich jedoch nach diesen bekannten Verfahren nicht in brauchbaren Ausbeuten dealkylieren.It is also known compounds with a heterocyclic amine moiety defurfurylate with selenium dioxide or with polyphosphoric acid (T. Denzel ot al, Arch. Pharm. (Weinheim) 309, 486 (1976)), Pyrrolo- * Pyrimidines, in position 7 are benzylated or furfurylated, however, can be according to these known processes do not dealkylate in useful yields.
Andere Pyrrolo-Pyrimidine sind bereits als Naturstoffe und als synthetisch hergestellte Verbindungen bekannt geworden (E.C. Taylor et al, J. Am. Chem. Soc. 86, 951 (1964)).Other pyrrolo-pyrimidines are already available as natural products and as synthetic compounds prepared become known (E.C. Taylor et al, J. Am. Chem. Soc. 86, 951 (1964)).
Die vorliegende Erfindung betrifft neue Pyrrolo-Pyrimidine der allgemeinen Formel I in welcher R für Wasserstoff, Amino, Hydroxy, Halogen, Mercapto, Alkylmercapto, Alkoxy, Alkylamino, Aralkylamino, Arylamino oder Furfurylamino steht, wobei die genannten Alkylreste gegebenenfalls durch Halogen substituiert sind, und wobei die genannten Arylreste gegebenenfalls substituiert sind durch Halogen, Alkyl, Trifluormethyl oder Alkoxy, und R1 und R2 gleich oder verschieden sind und jeweils für Alkyl oder Phenyl, welches gegebenenfalls durch Halogen, Trifluormethyl, Alkyl oder Alkoxy substituiert ist, stehen oder gemeinsam für eine Alkylenkette mit 2 bis 5 Kohlenstoffatomen stehen, welche gegebenenfalls durch Alkyl substituiert ist.The present invention relates to new pyrrolo-pyrimidines of the general formula I. in which R stands for hydrogen, amino, hydroxy, halogen, mercapto, alkylmercapto, alkoxy, alkylamino, aralkylamino, arylamino or furfurylamino, the alkyl radicals mentioned being optionally substituted by halogen, and the aryl radicals mentioned being optionally substituted by halogen, alkyl, Trifluoromethyl or alkoxy, and R1 and R2 are identical or different and each represent alkyl or phenyl, which is optionally substituted by halogen, trifluoromethyl, alkyl or alkoxy, or together represent an alkylene chain having 2 to 5 carbon atoms, which is optionally substituted by alkyl is.
Von besonderem Interesse sind Verbindungen der allgemeinen Formel I in welcher R für Wasserstoff, Amino, Hydroxy, Chlor, Brom, Mercapto, Alkoxy mit 1 bis 4 Kohlenstoffatomen, Alkylamino oder Alkylmercapto mit jeweils 1 bis 4 Kohlenstoffatomen in den Alkylgruppen oder für einen Furfurylaminorest, einen Benzylamino-oder Phenylaminorest steht, der gegebenenfalls durch Halogen, Trifluormethyl, Alkyl oder Alkoxy mit je 1 bis 4 Kohlenstoffatomen substituiert ist und R1 und R2 gleich oder verschieden sind und jeweils für Alkyl mit 1 bis 4 Kohlenstoffatomen oder Phenyl stehen oder gemeinsam für eine Alkylenkette mit 3 bis 4 Kohlenstoffatomen steht.Compounds of the general formula are of particular interest I in which R stands for hydrogen, amino, hydroxy, chlorine, bromine, mercapto, alkoxy with 1 to 4 carbon atoms, alkylamino or alkyl mercapto each with 1 to 4 carbon atoms in the alkyl groups or for a furfurylamino, benzylamino or phenylamino radical stands, which is optionally replaced by halogen, trifluoromethyl, alkyl or alkoxy with each 1 to 4 carbon atoms is substituted and R1 and R2 are identical or different are and each represent alkyl having 1 to 4 carbon atoms or phenyl or together represent an alkylene chain with 3 to 4 carbon atoms.
Dle erfindung betrifft ebenfalls ein Verfahren zur Iterstellung von Pyrrolo-Pyrimidinen der allgemeinen Formel 1, in welchem Pyrrolderivate der allgemeinen Formel II in welcher R1 und R2 die oben angegebene Bedeutung haben, mit Ameisensäurederivaten der allgemeinen Formel III in welcher R' für eine Aminogruppe oder eine Hydroxylgruppe steht, in Gegenwart von Ameisensäure und gegebenenfalls in Gegenwart von inerten organischen Lösungsmitteln bei erhöhter Temperatur umgesetzt werden zu substituierten Pyrrolo-Pyrimidin-Derivaten der allgemeinen Formel IV in welcher R', R1 und R2 die oben angegebene Bedeutung haben, dadurch gekennzeichnet, daß man die Verbindung der allgemeinen Formel In mit einem Überschuß von Säuren aus der Gruppe konzentrierte Salzsäure, Phosphorsäuren oder Polyphosphorsäure bei Temperaturen zwischen 200C und 1500C, gegebenenfalls in Gegenwart von Wasser dealkyliert, und gegebenenfalls die erhaltenen Verbindungen, in welcher R' eine Hydroxylgruppe bedeutet, mit Phosphoroxychlorid umsetzt, und das entstandene Chlorid nach bekannten Methoden mit Aminverbindungen oder Thiocarboxylverbindungen zu dem entsprechenden Amino- und Mercaptoderivaten des Substituenten R der allgemeinen Formel I umsetzt.The invention also relates to a process for the preparation of pyrrolo-pyrimidines of the general formula 1, in which pyrrole derivatives of the general formula II in which R1 and R2 have the meaning given above, with formic acid derivatives of the general formula III in which R 'stands for an amino group or a hydroxyl group, are reacted in the presence of formic acid and optionally in the presence of inert organic solvents at elevated temperature to give substituted pyrrolo-pyrimidine derivatives of the general formula IV in which R ', R1 and R2 have the meaning given above, characterized in that the compound of the general formula In with an excess of acids from the group of concentrated hydrochloric acid, phosphoric acids or polyphosphoric acid at temperatures between 200C and 1500C, optionally in the presence of Water dealkylates, and optionally the compounds obtained, in which R 'is a hydroxyl group, reacts with phosphorus oxychloride, and the resulting chloride is converted by known methods with amine compounds or thiocarboxyl compounds to give the corresponding amino and mercapto derivatives of the substituent R of general formula I.
Der letzte Verfahrensschritt ist nur erforderlich, wenn der Substituent R in der allgemeinen Formel I eine andere Bedeutung als Hydroxyl oder Amino hat. Die Umsetzung erfolgt analog dem von J. F. Gerster et al. J. Med.The last step is only required if the substituent R in the general formula I has a meaning other than hydroxyl or amino. The implementation takes place analogously to that of J. F. Gerster et al. J. Med.
Chem. 10, 326 (t967) beschriebenen Verfahren.Chem. 10, 326 (t967).
Ein besonders vorteilhaftes Verfahren besteht in der Verwendung von Polyphösphorsäure bei dem Dealkylierungsschritt.A particularly advantageous method consists in the use of Polyphosphoric acid in the dealkylation step.
Die Reaktiontemperatur konn in einem tJrOaren Be reich variiert werden. Man arbeitet im allgemeinen zwischen 20 und 100C, vorzugsweise zwischen 50 und 100°C.The reaction temperature can be varied within a range of 100%. In general, between 20 and 100.degree. C., preferably between 50 and 100.degree. C., are used.
Bei der Durchführung der Dealkylierung setzt man die in Frage kommende Säure in großem Ueberschuß ein. Vorzugsweise wird auf 1 Gew.-Teil der Pyrrolo-Pyrimlt verbindung der allgemeinen Formel IV die in Frage kommende Säure in einem überschuß von 2 bis 25 Cow.-To n, insbesondere von 5 bis 10 Gew.-Teilen eingesetzt. Die Reaktion kann je nach Art der eingesetzten Säure sowohl in Suspension als auch in Lösung durchgeführt werden.When carrying out the dealkylation, the one in question is used Acid in large excess. Preferably, 1 part by weight of the pyrrolo-pyrimlt is used compound of the general formula IV the acid in question in an excess from 2 to 25 cow tons, in particular from 5 to 10 parts by weight, are used. The reaction can, depending on the type of acid used, either in suspension or in solution be performed.
Die Aufarbeitung erfolgt in üblicher Weise durch Verdünnen des Reaktionsansatzes mit Wasser und anschließender Neutralisation mit einer Base, vorzugsweise mit Alkalihydroxyden oder mit konzentrierter Ammoniaklösung. Anschließend wird der ausgefallene Niederschlag aus geeigneten inerten organischen Lösungsmitteln, welche gegebenenfalls mit Wasser gemischt sind , kristallisiert. Als geeignete inerte Lösungsmittel seien beispielsweise genannt, Kohlenwasserstoffe wie Toluol, Benzol, Petrolether, Alkohole wie Methanol, Ethanol oder Butanol.Working up is carried out in the customary manner by diluting the reaction mixture with water and subsequent neutralization with a base, preferably with alkali hydroxides or with concentrated ammonia solution. Then the deposited precipitate from suitable inert organic solvents, which optionally with water are mixed, crystallized. Suitable inert solvents are, for example called, hydrocarbons such as toluene, benzene, petroleum ether, alcohols such as methanol, Ethanol or butanol.
Die vorliegende Erfindung betrifft auch die neuen substituierten Pyrrolo-Pyrimidinderivate der allgemeinen Formel IV in welcher R', R1 und R2 die oben angegebene Bedeutung haben.The present invention also relates to the new substituted pyrrolo-pyrimidine derivatives of the general formula IV in which R ', R1 and R2 have the meaning given above.
Diese Verbindungen der Formel IV sind bisher noch nicht bekanntgeworden, können jedoch nach dem oben angegebenen Verfahren in einfacher Weise hergestellt werden.These compounds of the formula IV have not yet become known, can, however, be prepared in a simple manner by the above-mentioned process will.
Bei Kenntnis des Standes der Technik konnte nicht erwartet werden, daß die Phenylethylgruppe sich bei der Einwirkung.von Säuren von der 7-Position des Pyrrolo-Pyrimidinringes in.Ausbeuten von mehr als 80 % der Theorie abspalten ließ. Im Hinblick auf die Erfahrungen von F.-W Korte, (Methodicum Chimicum 6, Seite 598, (1974)) ist eine Debenzylierung mit Polyphosphorsäure nicht ohne weiteres möglich. Solche Debenzylierungen lassen sich zwar hydrogenolytisch in einigen Fällen mit relativ niederen Ausbeuten durchführen. Eine hydrogenolytische Dealkylierung der allgemeinen Formel IV-konnte jedoch nicht durchgeführt werden. Der Stand.der Technik gab somit keinerlei Hinweis auf das erfindungsgemäße Verfahren. Man hätte vielmehr erwarten müssen, das bei den zum Teil recht hohen Reaktionstempe.raturen durch die Anwesenheit von starken Säuren das heterocyclische Ringsystem göffnet oder zumindest verändert wUrde. Es ist als ausgesprochen Überraschend zu benzeichnen daß man durch die erfindungsgem&ße Dealkylierung die neuen Verbindungen der allgemeinen Formel I in sehr hoher Reinheit und in einer Ausbeute, die deutlich Ueber 80 * der Theorie liegt, erhalten kann.With knowledge of the state of the art, it could not be expected that the phenylethyl group changes from the 7-position when exposed to acids of the pyrrolo-pyrimidine ring in yields of more than 80% of theory let. With regard to the experiences of F.-W Korte, (Methodicum Chimicum 6, p 598, (1974)) debenzylation with polyphosphoric acid is not easily possible. Such debenzylations can be carried out hydrogenolytically in some cases perform relatively low yields. A hydrogenolytic dealkylation of the However, general formula IV could not be carried out. The state of the art thus gave no indication of the method according to the invention. One would rather have have to expect that with the sometimes quite high reaction temperatures by the The presence of strong acids opens or at least opens the heterocyclic ring system changed. It is to be described as extremely surprising that one goes through the dealkylation according to the invention the new compounds of the general formula I in very high Purity and in a yield that is clearly above 80 * based on theory.
Bei der Herstellung von Verbindungen der allgemeinen Formel IV in welcher R' Hydroxyl bedeutet ist es zweckmäßig, als Reaktionspartner der allgemeinen Formel III Ameisensäure in 10 bis 30 molarem Überschuß einzusetzen. Bei der Herstellung von Verbindungen der allgemeinen Formel IV in welcher R' eine Amingruppe bedeutet, wird vorzugsweise Formamid (III) in entsprechendem Überschuß eingesetzt.In the preparation of compounds of the general formula IV in which R 'hydroxyl is useful as a reactant of the general Formula III to use formic acid in a 10 to 30 molar excess. In the preparation of of compounds of the general formula IV in which R 'denotes an amine group, formamide (III) is preferably used in an appropriate excess.
Die als Ausgangsverbindungen verwendeten Pyrrol-Derivate der Formel II lassen sich nach bekannten Methoden herstellen durch Kondensation von Hydroxyketonen wie z.B. Benzoin, Acetoin oder Adipoin mit dem Amin des Phenylethyls in Gegenwart von katalytischen Mengen einer starken Säure wie z.B. Salzsäure oder p-Toluolsulfonsäure, bei erhöhter Temperatur zu oC -Aminoketonen. Diese cr -Aminoketone werden anschließend mit Malonsäuredinitril zu den Verbindungen der allgemeinen Formel II kondensiert. Es hat sich herausgestellt, daß die Verwendung von D- oder L-Phenylethylamin ohne Einfluß auf die Kondensationsreaktion ist. Zweckmäßigerweise kann daher das Racemat eingesetzt werden.The pyrrole derivatives of the formula used as starting compounds II can be prepared by known methods by condensation of hydroxy ketones such as benzoin, acetoin or adipoin with the amine of phenylethyl in the presence of catalytic amounts of a strong acid such as hydrochloric acid or p-toluenesulfonic acid, at elevated temperature to oC -aminoketones. These cr -amino ketones are subsequently condensed with malononitrile to give the compounds of general formula II. It has been found that the use of D- or L-phenylethylamine without Influence on the condensation reaction. Appropriately, therefore, the racemate can be used.
Die Aufarbeitung der pyrrol-Derivate der allgemeinen Formel II erfolgt nach bekannten Methoden durch Abdampfen des Lösungsmittels und Rekristallisation des Rückstandes aus geeigneten Lösungsmitteln.The pyrrole derivatives of the general formula II are worked up according to known methods by evaporation of the solvent and recrystallization the residue from suitable solvents.
Die Pyrrolo-Pyrimidlnderivate der allgemeinen Formel IV sind bisher noch nicht bekannt geworden. Sie lassen sich jedoch nach dem oben angegebenen Reaktionsschema durch Umsetzung der Pyrrolverbindungen der Formel II mit Ameisensäurederivaten der Formel III in Gegenwart von inerten organischen Lösungsmitteln, insbesondere von Dimethylformamid, bei Temperaturen zwischen 80 bis 1300C erhalten. Die Isolierung und Aufarbeitung der Verbindung der Formel IV erfolgt nach üblichen Methoden durch Ausfällen in der Kälte, Abfiltrieren und Rekristallisieren aus geeigneten Lösungsmitteln.The Pyrrolo-Pyrimidlnderivate of the general formula IV are so far not yet known. However, they can be according to the reaction scheme given above by reacting the pyrrole compounds of the formula II with formic acid derivatives of Formula III in the presence of inert organic solvents, in particular of Dimethylformamide, obtained at temperatures between 80 and 1300C. The isolation The compound of the formula IV is worked up by customary methods Precipitation in the cold, filtration and recrystallization from suitable solvents.
Die erfindungsgemäßen. Verbindungen der allgemeinen Formel I stellen wertvolle Ausgangsprodukte für die Synthese von biologisch aktiven Wirkstoffen, insbesondere von Antiphlogistika und von Stoffen mit Wirkung auf das zentrale Nervensystem dar. Aus ihnen lassen sich in einfacher Weise durch Substitution des Stickstoffs in 7-Position unterschiedliche Pyrrolo-Pyrimidinderivate mit wertvollen Eigenschaften herstellen (vgl. DT-OS 28 18 676).The invention. Compounds of general formula I represent valuable starting products for the synthesis of biologically active ingredients, in particular anti-inflammatory drugs and substances that have an effect on the central nervous system from them can be in a simple manner by substitution of nitrogen in the 7-position different pyrrolo-pyrimidine derivatives with valuable properties (see DT-OS 28 18 676).
Neben ihrer Eigenschaft als Ausgangsprodukte für chemische Synthesen besitzen die Verbindungen der allgemeinen Formel I ihrerseits selbst wertvolle pharmakologische Eigenschaften. Sie besitzen z.B.In addition to their properties as starting materials for chemical syntheses The compounds of general formula I themselves have valuable pharmacological properties Properties. You have e.g.
entzündungshemmende Wirkung und eignen sich daher xur Herstsllung von Arzneimittelzubereitungen.anti-inflammatory effect and are therefore suitable for manufacture of pharmaceutical preparations.
Die folgenden Beispiele sollen die Erfindung erläutern ohne sie zu beschränken.The following examples are intended to explain the invention without illustrating it restrict.
Beispiele für die Herstellung von Verbindungen der allgemeinen Formel I 1) 4-Amino-5,6-dimethyl-7H-pyrrolo[2,3-d]-pyrimidin 5,32 g (0,02 Mol) 4-Amino-5,6 dimethyl-7H-7-phenylethylpyrrolo[2,3-d]pyrimidin werden in 80 g Polyphosphorsäure bei 600C drei Stunden gerührt. Nach der Hydrolyse mit Wasser wird mit konzentrierter Ammoniaklösung -neutralisiert. Die. ausgefallenen Kristalle werden mit Wasser gewaschen und aus Ethanol umkristallisiert.Examples of the preparation of compounds of the general formula I 1) 4-Amino-5,6-dimethyl-7H-pyrrolo [2,3-d] -pyrimidine 5.32 g (0.02 mole) 4-amino-5,6 dimethyl-7H-7-phenylethylpyrrolo [2,3-d] pyrimidine are dissolved in 80 g of polyphosphoric acid stirred at 600C for three hours. After hydrolysis with water, it is concentrated with Ammonia solution -neutralized. The. precipitated crystals are washed with water and recrystallized from ethanol.
Fp. 2810C Ausbeute 4,55 g (93,6 % der Theorie) Analog dem vorstehend beschriebenen Beispiel wurde hergestellt: 2) 4-Amino-5,6-diphenyl-7H-pyrroloL2,3-41pyrimidin Fp. 3260C Ausbeute 4,6 g (81,3 % der Theorie) 3) 4-Hydroxy-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin Fp. 362"C Ausbeute 3,10 g (95,1 % der Theorie) 4) 4-Hydroxy-.,6-tetramethylen-7H-pyrroloE,3-d7pyrimidin Fp. 2970C Ausbeute 1,45 g (76,7 * der Theorie) 5) 4-Hydroxy-5,6-diphenyl-7H-pyrrolo[2,3-d]pyrimidin Fp. 3650C Ausbeute 1,95 g (67,9 der Theorie) Beispiel 6 4-Chloro-5,6-dimethyl-7H-pyrrolo[2,3-d] -dpyrimidin 1,83 g (0,01- Mol) 4-Hydroxy-5 ,6-dimethyl-7H-pyrrolo 2,3-d,7pyrimidin werden in 30 ml Phosphoroxychlorid vier Stunden am Rückfluß gekocht. Nach dem Erkalten wird der Überschuß an Lösungsmittel im Vakuum abgezogen, der Rückstand hydrolysiert und aus Ethanol umkristallisiert. Melting point 2810C, yield 4.55 g (93.6% of theory) analogous to that above Example described was prepared: 2) 4-Amino-5,6-diphenyl-7H-pyrroloL2,3-41pyrimidine M.p. 3260C, yield 4.6 g (81.3% of theory) 3) 4-hydroxy-5,6-dimethyl-7H-pyrrolo [2,3-d] pyrimidine Mp. 362 "C, yield 3.10 g (95.1% of theory) 4) 4-Hydroxy -., 6-tetramethylene-7H-pyrroloE, 3-d7pyrimidine M.p. 2970C, yield 1.45 g (76.7 * of theory) 5) 4-hydroxy-5,6-diphenyl-7H-pyrrolo [2,3-d] pyrimidine Melting point 3650C, yield 1.95 g (67.9 of theory). Example 6 4-Chloro-5,6-dimethyl-7H-pyrrolo [2,3-d] -dpyrimidine 1.83 g (0.01 mol) of 4-hydroxy-5, 6-dimethyl-7H-pyrrolo 2,3-d, 7-pyrimidine are refluxed for four hours in 30 ml of phosphorus oxychloride. After cooling down the excess solvent is drawn off in vacuo and the residue is hydrolyzed and recrystallized from ethanol.
Fp. 2480C Ausbeute 1,4 g (77,3% der Theorie) Beispiel 7 4-Benzylamino-5,6-dimethyl-7H-pyrrolo[2,3]pyrimidin 1,;81 g (0,01. Mol) 4-Chloro-5,6-dimethyl-7H-pyrrolo [2,3-d]pyrimidin werden. in einem Überschuß von Benzylamin fünf Stunden am Rückfluß gekocht..Die beim Erkalten ausfallenden Kristalle werden aus Ethanol umkristallisiert.Melting point 2480C, yield 1.4 g (77.3% of theory). Example 7 4-Benzylamino-5,6-dimethyl-7H-pyrrolo [2,3] pyrimidine 1. 81 g (0.01 mol) of 4-chloro-5,6-dimethyl-7H-pyrrolo [2,3-d] pyrimidine will. refluxed in an excess of benzylamine for five hours Crystals which precipitate on cooling are recrystallized from ethanol.
Fp. 2120C Ausbeute 1,7 g (67,9 % der, Theorie) Beispiel 8 4-Mercapto-5,6-dimethyl-7B-pyrrolof2,3-dgpyrimidin 1,81 g (0,01 Mol) 4-Chloro-5,6-dimethyl-7H-pyrrolo [7,3-d]pyrimidin werden mit einem Überschuß an Thioharnstoff in Ethanol vier Stunden unter Rückfluß gekocht. Die beim Erkalten ausfallenden Kristalle werden aus Ethanol umkristallisiert.M.p. 2120C Yield 1.7 g (67.9% of theory) Example 8 4-Mercapto-5,6-dimethyl-7B-pyrrolof2,3-dg-pyrimidine 1.81 g (0.01 mol) of 4-chloro-5,6-dimethyl-7H-pyrrolo [7,3-d] pyrimidine are treated with a Excess thiourea in ethanol refluxed for four hours. The at Crystals which precipitate when cooling down are recrystallized from ethanol.
Fp. 3150C Ausbeute 1,30 g (66,4 % der Theorie) Beispiel 9 4-Furfurylamino-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin 1,81 g (0,01 Mol) 4-Chlor-5,6-dimethyl-7H-pyrrolo ),3-dZpyrimidin werden mit einem Überschuß an Furfurylamin in Ethanol £ünf Stunden am Rückfluß gekocht. Die beim Erkalten ausfallenden Kristalle werden aus Ethanol umkristallisiert.Mp. 3150C Yield 1.30 g (66.4% of theory) Example 9 4-Furfurylamino-5,6-dimethyl-7H-pyrrolo [2,3-d] pyrimidine 1.81 g (0.01 mol) of 4-chloro-5,6-dimethyl-7H-pyrrolo), 3-dZpyrimidine are mixed with a Excess furfurylamine in ethanol refluxed for five hours. The at Crystals which precipitate when cooling down are recrystallized from ethanol.
Fp. 199°C Ausbeute 1,4 g (57,9 % der Theorie) Analog der vorstehend beschriebenen Verbindung wurde hergestellt: Beispiel 10 4-(p-Bromanilino-)5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin Fp. 3080C Ausbeute 1,9 g (60,9 % der Theorie)Mp. 199 ° C, yield 1.4 g (57.9% of theory) Analogue of the compound described above was prepared: Example 10 4- (p-bromoanilino) 5,6-dimethyl-7H-pyrrolo [2,3-d] pyrimidine Mp. 3080C, yield 1.9 g (60.9% of theory)
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19803036390 DE3036390A1 (en) | 1980-09-26 | 1980-09-26 | Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19803036390 DE3036390A1 (en) | 1980-09-26 | 1980-09-26 | Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid |
Publications (1)
Publication Number | Publication Date |
---|---|
DE3036390A1 true DE3036390A1 (en) | 1982-05-13 |
Family
ID=6112948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19803036390 Withdrawn DE3036390A1 (en) | 1980-09-26 | 1980-09-26 | Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE3036390A1 (en) |
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4595530A (en) * | 1983-03-17 | 1986-06-17 | Takeda Chemical Industries, Ltd. | Thiodeazapurine derivatives |
US4892865A (en) * | 1987-12-01 | 1990-01-09 | The Regents Of The University Of Michigan | Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents |
US4927830A (en) * | 1988-04-08 | 1990-05-22 | The Regents Of The University Of Michigan | Acyclic pyrrolo[2,3-D]pyrimidine analogs as antiviral agents |
US4968686A (en) * | 1988-04-08 | 1990-11-06 | The Regents Of The University Of Michigan | Acyclic pyrrolo [2,3-d]pyrimidine analogs as antiviral agents |
US5248672A (en) * | 1990-11-01 | 1993-09-28 | The Regents Of The University Of Michigan | Polysubstituted benzimidazole nucleosides as antiviral agents |
EP0682027A1 (en) | 1994-05-03 | 1995-11-15 | Ciba-Geigy Ag | Pyrrolopyrimidine derivatives with antiproliferative action |
WO1997032879A1 (en) * | 1996-03-06 | 1997-09-12 | Novartis Ag | 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINES |
USRE36187E (en) * | 1988-04-08 | 1999-04-06 | The Regents Of The University Of Michigan | Acyclic pyrrolo 2,3-d!pyrimidine analogs as antiviral agents |
WO2000017203A1 (en) * | 1998-09-18 | 2000-03-30 | Basf Aktiengesellschaft | Pyrrolopyrimidines as protein kinase inhibitors |
US6140332A (en) * | 1995-07-06 | 2000-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
US6251911B1 (en) | 1996-10-02 | 2001-06-26 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
WO2001072751A1 (en) * | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
US6395733B1 (en) * | 1995-06-07 | 2002-05-28 | Pfizer Inc | Heterocyclic ring-fused pyrimidine derivatives |
US6660744B1 (en) | 1999-09-17 | 2003-12-09 | Abbott Gmbh & Co. Kg | Pyrazolopyrimidines as therapeutic agents |
US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
US7071199B1 (en) | 1999-09-17 | 2006-07-04 | Abbott Gmbh & Cco. Kg | Kinase inhibitors as therapeutic agents |
US7335667B2 (en) * | 2004-12-22 | 2008-02-26 | Incyte Corporation | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as Janus kinase inhibitors |
US7598257B2 (en) | 2005-12-13 | 2009-10-06 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
JP2009542749A (en) * | 2006-07-10 | 2009-12-03 | デフェロゲン アクチェンゲゼルシャフト | Pyrrolopyrimidine for pharmaceutical composition |
US7834022B2 (en) | 2007-06-13 | 2010-11-16 | Incyte Corporation | Metabolites of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
US8158616B2 (en) | 2008-03-11 | 2012-04-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
US8513270B2 (en) | 2006-12-22 | 2013-08-20 | Incyte Corporation | Substituted heterocycles as Janus kinase inhibitors |
US8563541B2 (en) | 2005-09-22 | 2013-10-22 | Incyte Corporation | Azepine inhibitors of Janus kinases |
US8604043B2 (en) | 2009-05-22 | 2013-12-10 | Incyte Corporation | 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
US8648068B2 (en) | 2010-02-26 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions |
US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US8722693B2 (en) | 2007-06-13 | 2014-05-13 | Incyte Corporation | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US8754079B2 (en) | 2010-02-26 | 2014-06-17 | Boehringer Ingelheim International Gmbh | Cycloalkyl containing thienopyrimidines for pharmaceutical compositions |
US8765734B2 (en) | 2010-03-10 | 2014-07-01 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US8853193B2 (en) | 2010-02-26 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
US8933085B2 (en) | 2010-11-19 | 2015-01-13 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
US8987443B2 (en) | 2013-03-06 | 2015-03-24 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9358229B2 (en) | 2011-08-10 | 2016-06-07 | Novartis Pharma Ag | JAK PI3K/mTOR combination therapy |
US9359358B2 (en) | 2011-08-18 | 2016-06-07 | Incyte Holdings Corporation | Cyclohexyl azetidine derivatives as JAK inhibitors |
US9487521B2 (en) | 2011-09-07 | 2016-11-08 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
US9512161B2 (en) | 2009-10-09 | 2016-12-06 | Incyte Corporation | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US9655854B2 (en) | 2013-08-07 | 2017-05-23 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
US9993480B2 (en) | 2011-02-18 | 2018-06-12 | Novartis Pharma Ag | mTOR/JAK inhibitor combination therapy |
US10166191B2 (en) | 2012-11-15 | 2019-01-01 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
US10758543B2 (en) | 2010-05-21 | 2020-09-01 | Incyte Corporation | Topical formulation for a JAK inhibitor |
US10899736B2 (en) | 2018-01-30 | 2021-01-26 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
US11304949B2 (en) | 2018-03-30 | 2022-04-19 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
-
1980
- 1980-09-26 DE DE19803036390 patent/DE3036390A1/en not_active Withdrawn
Cited By (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4595530A (en) * | 1983-03-17 | 1986-06-17 | Takeda Chemical Industries, Ltd. | Thiodeazapurine derivatives |
US4892865A (en) * | 1987-12-01 | 1990-01-09 | The Regents Of The University Of Michigan | Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents |
USRE36187E (en) * | 1988-04-08 | 1999-04-06 | The Regents Of The University Of Michigan | Acyclic pyrrolo 2,3-d!pyrimidine analogs as antiviral agents |
US4927830A (en) * | 1988-04-08 | 1990-05-22 | The Regents Of The University Of Michigan | Acyclic pyrrolo[2,3-D]pyrimidine analogs as antiviral agents |
US4968686A (en) * | 1988-04-08 | 1990-11-06 | The Regents Of The University Of Michigan | Acyclic pyrrolo [2,3-d]pyrimidine analogs as antiviral agents |
US6093698A (en) * | 1990-11-01 | 2000-07-25 | The Regents Of The University Of Michigan | Polysubstituted benzimidazoles as antiviral agents |
US5712255A (en) * | 1990-11-01 | 1998-01-27 | The Regents Of The University Of Michigan | Treatment of herpes infections with polysubstituted benzimidazoles |
US5574058A (en) * | 1990-11-01 | 1996-11-12 | The Regents Of The University Of Michigan | Polysubstituted benzimidazoles as antiviral agents |
US5646125A (en) * | 1990-11-01 | 1997-07-08 | The Regents Of The University Of Michigan | Polysubstituted benzimidazoles as antiviral agents |
US5654283A (en) * | 1990-11-01 | 1997-08-05 | The Regents Of The University Of Michigan | Polysubstituted benzimidazoles as antiviral agents |
US5665709A (en) * | 1990-11-01 | 1997-09-09 | The Regents Of The University Of Michigan | Polysubstituted benzimidazole nucleosides as antiviral agents |
US5248672A (en) * | 1990-11-01 | 1993-09-28 | The Regents Of The University Of Michigan | Polysubstituted benzimidazole nucleosides as antiviral agents |
US5360795A (en) * | 1990-11-01 | 1994-11-01 | The Regents Of The University Of Michigan | Polysubstituted benzimidazoles as antiviral agents |
US5705490A (en) * | 1990-11-01 | 1998-01-06 | The Regents Of The University Of Michigan | Polysubstituted benzimidazoles as antiviral agents |
US5686457A (en) * | 1994-05-03 | 1997-11-11 | Novartis Corporation | Pyrrolopyrimidine derivatives having pharmacological activity |
AU695244B2 (en) * | 1994-05-03 | 1998-08-13 | Novartis Ag | Pyrrolopyrimidine derivatives having pharmacological activity |
US6096749A (en) * | 1994-05-03 | 2000-08-01 | Novartis Corporation | Pyrrolopyrimidine derivatives having pharmacological activity |
EP0682027A1 (en) | 1994-05-03 | 1995-11-15 | Ciba-Geigy Ag | Pyrrolopyrimidine derivatives with antiproliferative action |
US6395733B1 (en) * | 1995-06-07 | 2002-05-28 | Pfizer Inc | Heterocyclic ring-fused pyrimidine derivatives |
US6140332A (en) * | 1995-07-06 | 2000-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
WO1997032879A1 (en) * | 1996-03-06 | 1997-09-12 | Novartis Ag | 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINES |
US6251911B1 (en) | 1996-10-02 | 2001-06-26 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
WO2000017203A1 (en) * | 1998-09-18 | 2000-03-30 | Basf Aktiengesellschaft | Pyrrolopyrimidines as protein kinase inhibitors |
US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
US6660744B1 (en) | 1999-09-17 | 2003-12-09 | Abbott Gmbh & Co. Kg | Pyrazolopyrimidines as therapeutic agents |
US7071199B1 (en) | 1999-09-17 | 2006-07-04 | Abbott Gmbh & Cco. Kg | Kinase inhibitors as therapeutic agents |
WO2001072751A1 (en) * | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
US8053433B2 (en) | 2004-12-22 | 2011-11-08 | Ineyte Corporation | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors |
US9090611B2 (en) | 2004-12-22 | 2015-07-28 | Incyte Corporation | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors |
US9580419B2 (en) | 2004-12-22 | 2017-02-28 | Incyte Corporation | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as Janus kinase inhibitors |
US8741895B2 (en) | 2004-12-22 | 2014-06-03 | Incyte Corporation | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as Janus kinase inhibitors |
US9879010B2 (en) | 2004-12-22 | 2018-01-30 | Incyte Holdings Corporation | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b] pyrimidin-5-yl-amines as Janus kinase inhibitors |
US7335667B2 (en) * | 2004-12-22 | 2008-02-26 | Incyte Corporation | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as Janus kinase inhibitors |
US8445488B2 (en) | 2004-12-22 | 2013-05-21 | Incyte Corporation | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as Janus kinase inhibitors |
US8835423B2 (en) | 2005-09-22 | 2014-09-16 | Incyte Corporation | Azepine inhibitors of janus kinases |
US8563541B2 (en) | 2005-09-22 | 2013-10-22 | Incyte Corporation | Azepine inhibitors of Janus kinases |
US7598257B2 (en) | 2005-12-13 | 2009-10-06 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
US9814722B2 (en) | 2005-12-13 | 2017-11-14 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
US8541425B2 (en) | 2005-12-13 | 2013-09-24 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US8946245B2 (en) | 2005-12-13 | 2015-02-03 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US10398699B2 (en) | 2005-12-13 | 2019-09-03 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
US10639310B2 (en) | 2005-12-13 | 2020-05-05 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US9974790B2 (en) | 2005-12-13 | 2018-05-22 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
US9079912B2 (en) | 2005-12-13 | 2015-07-14 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
US8415362B2 (en) | 2005-12-13 | 2013-04-09 | Incyte Corporation | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US8530485B2 (en) | 2005-12-13 | 2013-09-10 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US11331320B2 (en) | 2005-12-13 | 2022-05-17 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US9662335B2 (en) | 2005-12-13 | 2017-05-30 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
US11744832B2 (en) | 2005-12-13 | 2023-09-05 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US9206187B2 (en) | 2005-12-13 | 2015-12-08 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase |
US8933086B2 (en) | 2005-12-13 | 2015-01-13 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors |
JP2009542749A (en) * | 2006-07-10 | 2009-12-03 | デフェロゲン アクチェンゲゼルシャフト | Pyrrolopyrimidine for pharmaceutical composition |
US8697713B2 (en) | 2006-07-10 | 2014-04-15 | Boehringer Ingelheim International Gmbh | Pyrrolopyrimidines for pharmaceutical compositions |
US8841318B2 (en) | 2006-12-22 | 2014-09-23 | Incyte Corporation | Substituted heterocycles as janus kinase inhibitors |
US8513270B2 (en) | 2006-12-22 | 2013-08-20 | Incyte Corporation | Substituted heterocycles as Janus kinase inhibitors |
US10016429B2 (en) | 2007-06-13 | 2018-07-10 | Incyte Corporation | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US9376439B2 (en) | 2007-06-13 | 2016-06-28 | Incyte Corporation | Salts of the janus kinase inhibitor (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US8889697B2 (en) | 2007-06-13 | 2014-11-18 | Incyte Corporation | Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US7834022B2 (en) | 2007-06-13 | 2010-11-16 | Incyte Corporation | Metabolites of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US8722693B2 (en) | 2007-06-13 | 2014-05-13 | Incyte Corporation | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US11213528B2 (en) | 2007-06-13 | 2022-01-04 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US10463667B2 (en) | 2007-06-13 | 2019-11-05 | Incyte Incorporation | Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US8829013B1 (en) | 2007-06-13 | 2014-09-09 | Incyte Corporation | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US10610530B2 (en) | 2007-06-13 | 2020-04-07 | Incyte Corporation | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US8822481B1 (en) | 2007-06-13 | 2014-09-02 | Incyte Corporation | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US8420629B2 (en) | 2008-03-11 | 2013-04-16 | Incyte Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
US8158616B2 (en) | 2008-03-11 | 2012-04-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
US9216984B2 (en) | 2009-05-22 | 2015-12-22 | Incyte Corporation | 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors |
US9334274B2 (en) | 2009-05-22 | 2016-05-10 | Incyte Holdings Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US8604043B2 (en) | 2009-05-22 | 2013-12-10 | Incyte Corporation | 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
US9623029B2 (en) | 2009-05-22 | 2017-04-18 | Incyte Holdings Corporation | 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors |
US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9512161B2 (en) | 2009-10-09 | 2016-12-06 | Incyte Corporation | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US8853193B2 (en) | 2010-02-26 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
US8648068B2 (en) | 2010-02-26 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions |
US8754079B2 (en) | 2010-02-26 | 2014-06-17 | Boehringer Ingelheim International Gmbh | Cycloalkyl containing thienopyrimidines for pharmaceutical compositions |
US9999619B2 (en) | 2010-03-10 | 2018-06-19 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US10695337B2 (en) | 2010-03-10 | 2020-06-30 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US11285140B2 (en) | 2010-03-10 | 2022-03-29 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US8765734B2 (en) | 2010-03-10 | 2014-07-01 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US9464088B2 (en) | 2010-03-10 | 2016-10-11 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US11571425B2 (en) | 2010-05-21 | 2023-02-07 | Incyte Corporation | Topical formulation for a JAK inhibitor |
US12226419B2 (en) | 2010-05-21 | 2025-02-18 | Incyte Corporation | Topical formulation for a JAK inhibitor |
US10869870B2 (en) | 2010-05-21 | 2020-12-22 | Incyte Corporation | Topical formulation for a JAK inhibitor |
US10758543B2 (en) | 2010-05-21 | 2020-09-01 | Incyte Corporation | Topical formulation for a JAK inhibitor |
US11590136B2 (en) | 2010-05-21 | 2023-02-28 | Incyte Corporation | Topical formulation for a JAK inhibitor |
US11219624B2 (en) | 2010-05-21 | 2022-01-11 | Incyte Holdings Corporation | Topical formulation for a JAK inhibitor |
US8933085B2 (en) | 2010-11-19 | 2015-01-13 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
US10640506B2 (en) | 2010-11-19 | 2020-05-05 | Incyte Holdings Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors |
US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
US9993480B2 (en) | 2011-02-18 | 2018-06-12 | Novartis Pharma Ag | mTOR/JAK inhibitor combination therapy |
US9611269B2 (en) | 2011-06-20 | 2017-04-04 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US9023840B2 (en) | 2011-06-20 | 2015-05-05 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US10513522B2 (en) | 2011-06-20 | 2019-12-24 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US11214573B2 (en) | 2011-06-20 | 2022-01-04 | Incyte Holdings Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US9358229B2 (en) | 2011-08-10 | 2016-06-07 | Novartis Pharma Ag | JAK PI3K/mTOR combination therapy |
US9359358B2 (en) | 2011-08-18 | 2016-06-07 | Incyte Holdings Corporation | Cyclohexyl azetidine derivatives as JAK inhibitors |
US9487521B2 (en) | 2011-09-07 | 2016-11-08 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
US9718834B2 (en) | 2011-09-07 | 2017-08-01 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
US10166191B2 (en) | 2012-11-15 | 2019-01-01 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US11337927B2 (en) | 2012-11-15 | 2022-05-24 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
US11896717B2 (en) | 2012-11-15 | 2024-02-13 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
US10874616B2 (en) | 2012-11-15 | 2020-12-29 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US11576865B2 (en) | 2012-11-15 | 2023-02-14 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US11576864B2 (en) | 2012-11-15 | 2023-02-14 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US9714233B2 (en) | 2013-03-06 | 2017-07-25 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
US8987443B2 (en) | 2013-03-06 | 2015-03-24 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
US9221845B2 (en) | 2013-03-06 | 2015-12-29 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
US11045421B2 (en) | 2013-08-07 | 2021-06-29 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
US10561616B2 (en) | 2013-08-07 | 2020-02-18 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
US9655854B2 (en) | 2013-08-07 | 2017-05-23 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
US12151026B2 (en) | 2013-08-07 | 2024-11-26 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
US11278541B2 (en) | 2017-12-08 | 2022-03-22 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
US10899736B2 (en) | 2018-01-30 | 2021-01-26 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
US11304949B2 (en) | 2018-03-30 | 2022-04-19 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
US12280054B2 (en) | 2018-03-30 | 2025-04-22 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3036390A1 (en) | Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid | |
DE2847693A1 (en) | METHOD FOR PRODUCING PYRIMIDO- (6,1-A) -ISOCHINOLIN-2-ONES | |
DE69422795T2 (en) | METHOD FOR PRODUCING 9-AMINO CAMPTOTHECIN | |
DE2858259C2 (en) | 9,10-Dimathoxy-2,3,6,7-tetrahydro-4-H-pyrimido- (6,1-a) -isoquinolin-4-one derivatives and process for their preparation | |
DE1197466B (en) | Process for the preparation of new 5, 6, 7, 8-tetrahydropyrido- [4, 3-d] pyrimidines | |
DE1620694B2 (en) | Process for the preparation of 5-methyl-7-diethylamino-s-triazolo [1,5-a] pyrimidine and its salts with acids | |
DE2505297B2 (en) | Process for the preparation of 2-phenylamino-2-imidazoline derivatives substituted in the 2- and 6-positions of the phenyl nucleus | |
DE2165056C3 (en) | Process for the production of CMnazollnonen | |
DE2538620A1 (en) | PROCESS FOR THE PRODUCTION OF QUINOXALINE AND QUINAZOLINE DERIVATIVES | |
DD248593A1 (en) | PROCESS FOR PREPARING 4-BASED SUBSTITUTED THIENO / 2,3-D / PYRIMIDIN-6-YLCARBOXYANESEESTERS | |
DE1470367A1 (en) | Process for the preparation of 5,6-dihydro-6-oxopyrido [2,3-b] [1,4] benzoxazepines substituted in the 5-position | |
DD144409A1 (en) | PROCESS FOR THE PREPARATION OF 5-ALKYL-2-ROACHED BRACKET ON4-ACYLOXY-PHENYL POOR CLAUSE TO PYRIMIDINES | |
DE2433176C3 (en) | N-cyano-cyano-acetimidate and process for the preparation of 2-halopyrinüdinderivaten | |
EP0377437B1 (en) | Process for the preparation of 2,4-diamino-6-piperidinyl-pyrimidine-3-N-oxide | |
DE1962261C3 (en) | Process for the preparation of 2,6-bis (diethanolamino) -4,8-dipiperidinopyrimido [5,4-d] pyrimidine | |
DD226893A1 (en) | PROCESS FOR PREPARING ARYLAMINOSUBSTITUTED THIENO 2,3-D PYRIMIDINES | |
DE69127238T2 (en) | Process for the preparation of pyrido [1,2-a] pyrimidine derivatives | |
DE69026638T2 (en) | Process for the preparation of pyrido [1,2-a] pyrimidine derivatives | |
EP0983247B1 (en) | Method for producing aromatic bisimides | |
DE2003043C3 (en) | Process for the preparation of 2,6-bis (diethanolamino) -4,8-dipiperidino-pyrimido [5,4d] pyrimidine | |
DE2760278C2 (en) | ||
DE3707530A1 (en) | NEW SUBSTITUTED DIHALOGENPYRIDINE AND METHOD FOR THE PRODUCTION THEREOF AND ITS OTHER IMPLEMENTATION FOR PYRIDINE DICARBONIC ACID DIESTERS | |
EP0492254A1 (en) | N-(tert-Butoxycarbonyl)maleimide | |
DE1470354C (en) | 4H m Dithuno square bracket to 5.4 square bracket to pyrimidine and process ren for their production | |
DE2755637A1 (en) | METHOD FOR PRODUCING BLOOD PRESSURE-REDUCING 6,7-DIMETHOXY-4-AMINO-2 CORNER CLAMP ON 4- (2-FUROYL) -1-PIPERAZINYL CORNER CLAMP TO CHINAZOLINE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8130 | Withdrawal |